Evidence map›Paper›PMID 36123252›Full record

ArticleDrug and alcohol dependence2022

Use of COVID-19 testing in the first year of the COVID-19 pandemic among cohorts of people at the intersection of drug use and HIV.

Pamina M Gorbach, Alison D Rosen, Richard Moore, Steve Shoptaw, Brian Mustanski, Shruti H Mehta, Gregory D Kirk, Marianna K Baum, M-J Milloy, Kanna Hayashi and 5 more

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Pamina M GorbachDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Box 951772, CHS 41-295, Los Angeles, CA 90095-1772, USA. Electronic address: pgorbach@ucla.edu.
Alison D RosenDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Box 951772, CHS 41-295, Los Angeles, CA 90095-1772, USA.
Richard MooreDivision of General Internal Medicine, Johns Hopkins School of Medicine, 1830 E. Monument St., Baltimore, MD 21287, USA.
Steve ShoptawDepartment of Family Medicine, University of California Los Angeles, 10880 Wilshire Boulevard, Los Angeles, CA 90024, USA.
Brian MustanskiInstitute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University, 625 N. Michigan Ave, Chicago, IL 60611, USA.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA.
Gregory D KirkDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA.
Marianna K BaumDepartment of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8 Street, AHC-5, 326, Miami, FL 33199, USA.
M-J MilloyDepartment of Medicine, University of British Columbia, Vancouver, Canada; British Columbia Centre on Substance Use, Vancouver, Canada.
Kanna HayashiBritish Columbia Centre on Substance Use, Vancouver, Canada; School of Public Policy, Simon Fraser University, Vancouver, Canada.
Kora DeBeckBritish Columbia Centre on Substance Use, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada.
Michele KipkeUniversity of Southern California, Children's Hospital Los Angeles, CHL 4650 W. Sunset Blvd., Los Angeles, CA 90027, USA.
Shenghan LaiDepartment of Epidemiology and Public Health, School of Medicine, University of Maryland, Baltimore, MD, USA.
Suzanne SiminskiFrontier Science Foundation, 4033 Maple Road, Amherst, NY 14226, USA.
Marjan JavanbakhtDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Box 951772, CHS 41-295, Los Angeles, CA 90095-1772, USA.
University of California, Los Angeles · USBritish Columbia Centre on Substance Use · CAJohns Hopkins University · USChildren's Hospital of Los Angeles · USFlorida International University · USFrontier Science & Technology Research Foundation · USNorthwestern University · USUniversity of Maryland, Baltimore · US

Funding

The RADAR cohort study of multilevel Influences on HIV and substance useU01DA036939 · NIDA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Brian Mustanski, Michael E Newcomb · 2014 to 2026
$29.5M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
Young Men of Color Who Have Sex with Men Cohort StudyU01DA036926 · NIDA · CHILDREN'S HOSPITAL OF LOS ANGELES · PI GOLDBACH, JEREMY THOMAS, KIPKE, MICHELE D. · 2015 to 2024
$23.3M
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable PopulationsU01DA040381 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI BAUM, MARIANNA K · 2015 to 2022
$9.6M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersU01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2017 to 2024
$4.3M
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase IIU01MD017423 · NIMHD · FLORIDA INTERNATIONAL UNIVERSITY · PI BAUM, MARIANNA K · 2022 to 2023
$2.2M
NIDA NIH HHS U01 DA021525NIDA NIH HHS U01 DA036297NIDA NIH HHS U01 DA036926NIDA NIH HHS U01 DA036939NIDA NIH HHS U01 DA038886NIDA NIH HHS U01 DA040381NIMHD NIH HHS U01 MD017423
6 · The paper itself

Abstract

People living with (PLWH) and at risk for HIV and people who use drugs (PWUD) are at heightened risk for health consequences of COVID-19 because of compromised immunity and high comorbidities. We studied their use of COVID-19 testing during the first year of the COVID-19 pandemic. Eight NIDA funded cohorts across North America in the Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) administered multiple waves of a COVID-19 survey. Respondents were at least 18 years of age, half PLWH, and many active substance users. Wave one of the COVID-19 survey was May-November, 2020 and wave two October 2020-April 2021. Associations of COVID-19 testing with demographics, socio-demographics, substance use, and HIV-status were assessed. Of the 3762 responses from 2331 individuals, half reported ever COVID-19 testing (49.1 %), with 4.3 % reporting a positive test (163/3762 surveys=4.3 %) and 41.5 % of people reporting current symptoms reported having been tested. In multivariable analysis adjusting for age, sex, and cohort type associations with COVID-19 testing included African American/Black identification compared to Caucasian/white (adjusted odds ratio (AOR)= 0.68; 95 % confidence interval (CI) 0.53, 0.88); being unemployed (AOR=0.61; 95 % CI 0.51, 0.73), and living with HIV (AOR=0.76; 95 % CI0.65, 0.90). Findings from these C3PNO COVID-19 modules suggests that in the first year of the pandemic COVID-19 testing was not broadly accessed by these marginalized populations including PLWH and those unemployed. Factors associated with not testing may also parallel those for vaccination and identify populations needing better access to COVID-19 prevention.

Indexed as

COVID-19HIV InfectionsSubstance-Related DisordersBlack or African AmericanHumansPandemicsCOVID-19 pandemicCOVID-19 testingPeople living with HIVPeople who use substances

Identifiers

PMID36123252
PMCPMC9444299
OpenAlexW4294862255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.